HUTCHMED (China) Limited (HCM)
USD 15.0
(1.35%)
USD 15.0
(1.35%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 86.13 Million USD | 269.66% |
| 2022 | 23.3 Million USD | -31.6% |
| 2021 | 34.06 Million USD | -4.6% |
| 2020 | 35.71 Million USD | 7.94% |
| 2019 | 33.08 Million USD | 23.73% |
| 2018 | 26.73 Million USD | -10.83% |
| 2017 | 29.98 Million USD | -35.91% |
| 2016 | 46.78 Million USD | -6.43% |
| 2015 | 50 Million USD | -6.02% |
| 2014 | 53.2 Million USD | 3.29% |
| 2013 | 51.5 Million USD | 35.1% |
| 2012 | 38.12 Million USD | 26.92% |
| 2011 | 30.03 Million USD | 22.6% |
| 2010 | 24.5 Million USD | 196.7% |
| 2009 | 8.25 Million USD | 8.57% |
| 2008 | 7.6 Million USD | 15.89% |
| 2007 | 6.56 Million USD | -7.76% |
| 2006 | 7.11 Million USD | -3.66% |
| 2005 | 7.38 Million USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 85.7 Million USD | -0.5% |
| 2024 Q2 | 82.1 Million USD | 3.37% |
| 2023 Q3 | 82.2 Million USD | 104.76% |
| 2023 FY | 86.13 Million USD | 269.66% |
| 2023 Q1 | 40.14 Million USD | 72.3% |
| 2023 Q2 | 40.14 Million USD | 0.0% |
| 2023 Q4 | 86.13 Million USD | 4.78% |
| 2022 Q3 | 23.29 Million USD | 5474.16% |
| 2022 Q1 | 418 Thousand USD | -98.77% |
| 2022 Q4 | 23.3 Million USD | 0.0% |
| 2022 FY | 23.3 Million USD | -31.6% |
| 2022 Q2 | 418 Thousand USD | 0.0% |
| 2021 Q2 | 36.69 Million USD | -1.82% |
| 2021 FY | 34.06 Million USD | -4.6% |
| 2021 Q1 | 37.37 Million USD | 4.65% |
| 2021 Q4 | 34.06 Million USD | 0.0% |
| 2021 Q3 | 34.06 Million USD | -7.16% |
| 2020 Q4 | 35.71 Million USD | 6.58% |
| 2020 Q2 | 32.71 Million USD | 0.0% |
| 2020 Q1 | - USD | -100.0% |
| 2020 FY | 35.71 Million USD | 7.94% |
| 2020 Q3 | 33.5 Million USD | 2.42% |
| 2019 Q2 | 7.24 Million USD | -77.7% |
| 2019 Q4 | 30.81 Million USD | 655.38% |
| 2019 FY | 33.08 Million USD | 23.73% |
| 2019 Q1 | 32.47 Million USD | 17.03% |
| 2019 Q3 | 4.07 Million USD | -43.68% |
| 2018 FY | 26.73 Million USD | -10.83% |
| 2018 Q1 | - USD | -100.0% |
| 2018 Q4 | 27.75 Million USD | 0.0% |
| 2018 Q2 | 26.69 Million USD | 0.0% |
| 2017 Q2 | 46.85 Million USD | -19.83% |
| 2017 Q3 | 32.57 Million USD | -30.48% |
| 2017 Q1 | 58.44 Million USD | 24.91% |
| 2017 FY | 29.98 Million USD | -35.91% |
| 2017 Q4 | 29.98 Million USD | -7.93% |
| 2016 Q4 | 46.78 Million USD | -18.14% |
| 2016 FY | 46.78 Million USD | -6.43% |
| 2016 Q3 | 57.15 Million USD | 36.48% |
| 2016 Q2 | 41.87 Million USD | -26.46% |
| 2016 Q1 | 56.94 Million USD | 13.88% |
| 2015 Q1 | 60.45 Million USD | 13.63% |
| 2015 Q3 | 46.79 Million USD | -7.59% |
| 2015 Q4 | 50 Million USD | 6.85% |
| 2015 FY | 50 Million USD | -6.02% |
| 2015 Q2 | 50.64 Million USD | -16.23% |
| 2014 Q1 | 66.12 Million USD | 28.37% |
| 2014 FY | 53.2 Million USD | 3.29% |
| 2014 Q2 | 58.35 Million USD | -11.75% |
| 2014 Q4 | 53.2 Million USD | 0.0% |
| 2013 Q1 | 52.11 Million USD | 36.68% |
| 2013 FY | 51.5 Million USD | 35.1% |
| 2013 Q3 | 58.88 Million USD | 13.0% |
| 2013 Q2 | 52.11 Million USD | 0.0% |
| 2013 Q4 | 51.5 Million USD | -12.52% |
| 2012 Q3 | - USD | -100.0% |
| 2012 Q2 | 28.79 Million USD | 0.0% |
| 2012 FY | 38.12 Million USD | 26.92% |
| 2012 Q4 | 38.12 Million USD | 0.0% |
| 2011 FY | 30.03 Million USD | 22.6% |
| 2011 Q4 | 30.03 Million USD | 0.0% |
| 2010 Q2 | 16.76 Million USD | 0.0% |
| 2010 Q4 | 24.5 Million USD | 0.0% |
| 2010 FY | 24.5 Million USD | 196.7% |
| 2009 FY | 8.25 Million USD | 8.57% |
| 2009 Q4 | 8.25 Million USD | 0.0% |
| 2008 FY | 7.6 Million USD | 15.89% |
| 2007 FY | 6.56 Million USD | -7.76% |
| 2006 FY | 7.11 Million USD | -3.66% |
| 2005 FY | 7.38 Million USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Esperion Therapeutics, Inc. | 540.94 Million USD | 84.078% |
| Theratechnologies Inc. | 58.96 Million USD | -46.064% |
| Safety Shot Inc | 1.54 Million USD | -5460.519% |
| Cosmos Health Inc. | 12.42 Million USD | -593.266% |
| Cronos Group Inc. | 2.53 Million USD | -3291.067% |
| Ironwood Pharmaceuticals, Inc. | 715.53 Million USD | 87.963% |
| Kala Pharmaceuticals, Inc. | 36.32 Million USD | -137.125% |
| Organogenesis Holdings Inc. | 119.35 Million USD | 27.834% |
| Universe Pharmaceuticals INC | 5.48 Million USD | -1471.029% |
| ProPhase Labs, Inc. | 21.38 Million USD | -302.858% |
| Sonoma Pharmaceuticals, Inc. | 608 Thousand USD | -14066.283% |
| Dynavax Technologies Corporation | 256.91 Million USD | 66.475% |
| Radius Health, Inc. | 365.31 Million USD | 76.423% |
| China SXT Pharmaceuticals, Inc. | 2.64 Million USD | -3153.351% |
| Alvotech | 1.07 Billion USD | 91.991% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -12995.689% |
| Alpha Teknova, Inc. | 30.45 Million USD | -182.786% |
| Intra-Cellular Therapies, Inc. | 16.93 Million USD | -408.507% |
| SCYNEXIS, Inc. | 15.08 Million USD | -471.16% |
| Harrow Health, Inc. | 190.5 Million USD | 54.787% |
| Biofrontera Inc. | 5.39 Million USD | -1495.314% |
| DURECT Corporation | 20.74 Million USD | -315.169% |
| Supernus Pharmaceuticals, Inc. | 41.52 Million USD | -107.41% |
| ANI Pharmaceuticals, Inc. | 315.32 Million USD | 72.685% |
| OptiNose, Inc. | 131.74 Million USD | 34.625% |
| RedHill Biopharma Ltd. | 1.17 Million USD | -7242.759% |
| Aquestive Therapeutics, Inc. | 98.82 Million USD | 12.842% |
| Cumberland Pharmaceuticals Inc. | 18.42 Million USD | -367.38% |
| SIGA Technologies, Inc. | 1.46 Million USD | -5783.229% |
| Lifecore Biomedical, Inc. | 130.36 Million USD | 33.928% |
| Shineco, Inc. | 29.65 Million USD | -190.429% |
| Phibro Animal Health Corporation | 525.45 Million USD | 83.608% |
| Procaps Group S.A. | 285.93 Million USD | 69.877% |
| TherapeuticsMD, Inc. | 8 Million USD | -975.965% |
| Regencell Bioscience Holdings Limited | 59.8 Thousand USD | -143914.915% |
| Viatris Inc. | 18.12 Billion USD | 99.525% |
| Sunshine Biopharma, Inc. | 657.7 Thousand USD | -12995.689% |
| Rockwell Medical, Inc. | 13.43 Million USD | -540.903% |
| Incannex Healthcare Limited | 373 Thousand USD | -22991.421% |
| Aytu BioPharma, Inc. | 15.12 Million USD | -469.311% |
| Tilray Brands, Inc. | 387.31 Million USD | 77.762% |
| Collegium Pharmaceutical, Inc. | 674.28 Million USD | 87.226% |
| PetIQ, Inc. | 468.3 Million USD | 81.608% |
| Silver Spike Investment Corp. | - USD | -Infinity% |
| Neurocrine Biosciences, Inc. | 428.4 Million USD | 79.895% |
| Journey Medical Corporation | 17.73 Million USD | -385.792% |
| Alimera Sciences, Inc. | 67.39 Million USD | -27.793% |
| Petros Pharmaceuticals, Inc. | 8.27 Million USD | -940.658% |
| Assertio Holdings, Inc. | 40.91 Million USD | -110.527% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.08 Million USD | -7818.679% |
| Embecta Corp. | 1.63 Billion USD | 94.743% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -8237.02% |
| Procaps Group, S.A. | 285.93 Million USD | 69.877% |
| PainReform Ltd. | 86 Thousand USD | -100052.326% |
| Avadel Pharmaceuticals plc | 35.38 Million USD | -143.418% |
| Hempacco Co., Inc. | 13.72 Million USD | -527.571% |
| Talphera, Inc. | - USD | -Infinity% |
| Pacira BioSciences, Inc. | 586.04 Million USD | 85.303% |
| Alvotech | 1.07 Billion USD | 91.991% |
| Lantheus Holdings, Inc. | 616.94 Million USD | 86.039% |
| Kamada Ltd. | 8.74 Million USD | -884.468% |
| Indivior PLC | 281.6 Million USD | 69.414% |
| Currenc Group, Inc. | 31.94 Million USD | -169.634% |
| Evoke Pharma, Inc. | 5 Million USD | -1622.62% |
| Flora Growth Corp. | 3.67 Million USD | -2245.615% |
| Cyclo Therapeutics, Inc. | 1.03 Million USD | -8237.02% |
| Evolus, Inc. | 126.54 Million USD | 31.937% |
| Amphastar Pharmaceuticals, Inc. | 623.64 Million USD | 86.189% |
| Akanda Corp. | 3.99 Million USD | -2053.926% |